NeuroOne Medical received U.S. Food and Drug Administration 510(k) clearance to market its OneRF Ablation System for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NMTC:
- Options Volatility and Implied Earnings Moves This Week, December 11 – December 15, 2023
- NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14
- NeuroOne announces patent allowance for drug delivery using Neural Probe
- NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
- NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
